A phase I trial of Ad.hIFN-beta gene therapy for glioma (Q64376835)

2

0 references

Byron McKinney

3

0 references

Cheryl A Palmer

4

0 references

Steven Rosenfeld

5

0 references

Kevin Lillehei

6

0 references

Allan Hamilton

7

0 references

Betty K DeMasters

8

0 references

Kevin Judy

9

0 references

David Kirn

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

10

0 references

language of work or name

English

0 references

publication date

March 2008

0 references

published in

Molecular Therapy

0 references

volume

16

0 references

issue

3

0 references

page(s)

618-26

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Gene therapy for malignant glioma: current clinical status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

1 reference

7 January 2021

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Interferon beta adenoviral gene therapy in a patient with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021

Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300396

7 January 2021